Invivyd, Inc. — 2022 Q2 Form 10-Q summary
Issuer identification: The supplied filing is for Adagio Therapeutics, Inc. (Nasdaq: ADGI), not Invivyd, Inc. It covers the quarter and six months ended June 30, 2022, and was signed August 15, 2022. The summary below reflects the filing as provided.
Business context and reporting period
Adagio was a clinical-stage biopharmaceutical company developing antibody treatments and preventatives for infectious diseases. Its lead candidate, adintrevimab, targeted COVID-19. The company had not generated revenue and relied on external research, clinical, and manufacturing partners.
Key financial metrics
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $37.1 million | $129.2 million |
| Selling, general and administrative expense | $14.6 million | $23.3 million |
| Net loss | $51.0 million | $151.7 million |
| Operating cash used | Not separately stated | $116.4 million |
- At June 30, cash and cash equivalents were $474.9 million; there were no marketable securities. Current assets were $481.4 million and current liabilities $67.9 million.
- Total liabilities were $69.8 million, including operating lease liabilities; the balance sheet reports no borrowings or other financial debt.
- Accumulated deficit was $443.8 million. Gross margin and profit margin are not meaningful because the company had no revenue.
- Cash and cash equivalents declined $67.3 million in the first half. Investing activities provided $49.0 million, primarily from maturing Treasury securities; financing activities provided $0.1 million.
Material changes versus the prior comparable period
- Second-quarter net loss increased $6.3 million from $44.7 million; first-half net loss increased $68.3 million from $83.4 million.
- First-half R&D expense rose $60.0 million, mainly from higher adintrevimab manufacturing and clinical-trial costs and increased personnel expense. Second-quarter R&D rose only $2.1 million, as reduced manufacturing costs were partly offset by staffing and discovery costs.
- First-half SG&A increased $12.6 million, primarily from public-company costs, including professional fees and director and officer insurance.
- First-half operating cash use increased from $57.3 million to $116.4 million. The 2021 comparison included $334.8 million of financing proceeds, versus negligible financing cash in 2022.
- In April 2022, the company reduced binding WuXi manufacturing commitments from $159.4 million to $51.6 million, a $107.8 million reduction, and received a credit in the low eight figures against future services.
Outlook, commentary, risks, and unusual items
- Management estimated existing cash would fund operating expenses and capital needs into the second quarter of 2024; the company cautioned that this estimate depended on assumptions and it might need additional capital. The notes also state cash was expected to cover at least 12 months from issuance of the interim statements.
- Based on FDA feedback and adintrevimab’s markedly reduced in-vitro activity against Omicron BA.2, BA.4, and BA.5, the company paused its planned EUA submission. Enrollment in the EVADE and STAMP trials had been paused in January 2022. The filing says preliminary pre-Omicron analyses showed efficacy, but these results do not resolve the variant-related regulatory and commercial uncertainty.
- The company planned to take a combination of newer antibodies targeting distinct sites into clinical trials in Q1 2023. It also reported being on track to have more than 700,000 adintrevimab doses secured in 2022, while noting that future utility depended on variant susceptibility and authorization.
- Material risks include continued operating losses, need for future financing, uncertain regulatory pathways and product demand, variant escape, competition, dependence on WuXi as a sole-source manufacturer, supply-chain disruption, and reliance on third parties. The company reported no material legal proceedings.
- Unusual items included a $4.6 million reversal of SG&A stock-based compensation following the former CEO’s resignation, and termination of the TSRI research agreement in Q2, with licenses reverting to TSRI. In July, David Hering became CEO and received an option to purchase 2.0 million shares, with a potential additional grant tied to goals.
- The filing states disclosure controls were effective as of June 30, 2022, and there were no material changes in internal control during the quarter. It also notes a previously identified material weakness was considered remediated as of December 31, 2021.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Adagio Therapeutics, Inc. (ADGI), not Invivyd, Inc.
- Review the cash runway assumptions and reconcile the “at least 12 months” statement in the notes with management’s forecast into Q2 2024.
- Check subsequent FDA discussions, variant susceptibility data, trial status, and whether any EUA request or later regulatory pathway was pursued.
- Verify the timing and accounting treatment of the WuXi credit described as applied in August 2022, as well as remaining manufacturing obligations and supply concentration.
- Assess whether the planned 2023 antibody combination trials began and whether the company obtained additional financing or altered its development plans.